Ozanimod hydrochlorideProduct ingredient for Ozanimod

Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) ⁹ and was approved by the FDA on March 26, 2020.^10,11 The US approval was followed by the approval in Canada on October 2, 2020.¹⁴ In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.^12,13

MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.⁴ Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.⁵

In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular interferon beta-1a, a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.^1,6

ChemSpider

34984145

ChEMBL

CHEMBL3707246